Ginkgo Bioworks (DNA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of directors is on the agenda, with specific nominees for both Class A and Class B shareholders, including Ross Fubini, Christian Henry, Sri Kosuri, and Harry E. Sloan for Class A, and additional nominees Jason Kelly and Reshma Shetty for Class B.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is proposed.
Advisory vote to approve executive compensation is included as a proposal.
Shareholders are invited to vote virtually at the annual meeting scheduled for June 11, 2026.
Board of directors and corporate governance
Board recommends all director nominees for election, with Class A and Class B shareholders voting on slightly different slates.
Executive compensation and say-on-pay
Advisory vote on executive compensation is presented, allowing shareholders to express approval or disapproval.
Latest events from Ginkgo Bioworks
- Q1 2026 revenue fell 49% to $19M as restructuring improved cash burn and focus shifted to autonomous labs.DNA
Q1 20268 May 2026 - Shareholders will vote virtually on directors, auditor, and executive pay, focusing on equity-based compensation.DNA
Proxy filing29 Apr 2026 - Cash burn cut by 55% as focus shifts to autonomous labs and AI-driven automation partnerships.DNA
Q4 20253 Mar 2026 - Q2 2024 revenue dropped 30% as restructuring and $47.9M goodwill impairment hit results.DNA
Q2 20241 Feb 2026 - Shifting to a focused, platform-driven model with new tools and data services for biotech innovation.DNA
Morgan Stanley 22nd Annual Global Healthcare Conference21 Jan 2026 - Q3 revenue up 61% to $89M, loss narrows, and 2024 guidance raised to $215–235M.DNA
Q3 202414 Jan 2026 - Direct sales, biopharma partnerships, and automation drive growth and market leadership.DNA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Cost cuts, new tools, and automation drive efficiency, but 2025 outlook remains cautious.DNA
Q4 202427 Dec 2025 - Flexible $500M shelf registration targets synthetic biology, automation, and biosecurity growth.DNA
Registration Filing16 Dec 2025